On Thursday, Shares of Cliffs Natural Resources Inc (NYSE:CLF), gained 3.71% to $2.93.
Cliffs Natural Resources, declared that, effective October 5, 2015, it has terminated its Pellet Sale and Purchase Agreement with Essar Algoma. Cliffs’ decision was made as a result of Essar Algoma’s multiple and material breaches under the agreement. While the agreement has been terminated, Cliffs remains open to discussing supplying Essar with pellets on commercially reasonable terms compriseent with a just-in-time iron ore supply arrangement.
Cliffs Natural Resources Inc., a mining and natural resources company, produces iron ore and metallurgical coal. It operates five iron ore mines that produces iron ore pellets in Michigan and Minnesota; Koolyanobbing complex situated in northeast of the town of Southern Cross, which produces lump and fines iron ore; and two metallurgical coal mines located in Alabama and West Virginia.
Shares of PulteGroup, Inc. (NYSE:PHM), inclined 1.11% to $19.10, during its last trading session.
PulteGroup, declared that it will release its third quarter 2015 financial results before the market opens on Thursday, October 22, 2015. The Company will hold a conference call to discuss third quarter results that same day at 8:30 a.m. (ET).
PulteGroup, Inc., through its auxiliaries, engages in the homebuilding business; mortgage banking operations; and title operations in the United States. The company is involved in the acquisition and development of land primarily for residential purposes; and the construction of housing on land.
Finally, Eli Lilly and Co (NYSE:LLY), ended its last trade with 0.79% gain, and closed at $79.88.
Boehringer Ingelheim Pharmaceuticals, and Eli Lilly and Company, declared that Synjardy (empagliflozin/metformin hydrochloride) tablets are now available by prescription in pharmacies across the United States. The U.S. Food and Drug Administration (FDA) approved SYNJARDY at the end of August as an adjunct to diet and exercise to improve glycemic control in adults with T2D who are not adequately controlled on a regimen containing empagliflozin or metformin alone, or in patients already being treated with empagliflozin and metformin.
SYNJARDY is a combination of Jardiance® (empagliflozin) and metformin — two medicines with complementary mechanisms of action – to assist control blood glucose in people with T2D. Empagliflozin, a sodium glucose co-transporter-2 (SGLT2) inhibitor, removes excess glucose through the urine by blocking glucose re-absorption in the kidney. Metformin, a commonly prescribed initial treatment for T2D, lowers glucose production by the liver and its absorption in the intestine.
“Boehringer Ingelheim and Lilly are committed to assisting improve care for adults with type 2 diabetes,” said Thomas Seck, M.D., vice president, Clinical Development and Medical Affairs - Metabolism at Boehringer Ingelheim. “As part of that effort, we are proud to make SYNJARDY, the third product from our diabetes alliance containing JARDIANCE, available to patients soon after its FDA approval.”
Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates through two segments, Human Pharmaceutical Products and Animal Health Products. The company offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
